Horizon Therapeutics Public Ltd Co Research and Development in Process
Horizon Therapeutics Public Ltd Co reported Research and Development in Process of $52.25 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-01.
Discontinued › Notes
us-gaap:ResearchAndDevelopmentInProcess · last filed 2023-03-01
- Horizon Therapeutics Public Ltd Co research and development in process for the quarter ending 2022-12-31 was $37.25M, a 23.87% increase year-over-year.
- Horizon Therapeutics Public Ltd Co research and development in process for the quarter ending 2022-09-30 was $13.00M.
- Horizon Therapeutics Public Ltd Co research and development in process for the quarter ending 2022-06-30 was $0.00.
- Horizon Therapeutics Public Ltd Co research and development in process for the quarter ending 2022-03-31 was $2.00M.
- Horizon Therapeutics Public Ltd Co research and development in process for fiscal 2022 was $52.25M, a 25.43% decline from fiscal 2021.
- Horizon Therapeutics Public Ltd Co research and development in process for fiscal 2021 was $70.07M, a 9.60% decline from fiscal 2020.
- Horizon Therapeutics Public Ltd Co research and development in process for fiscal 2020 was $77.52M.
- Horizon Therapeutics Public Ltd Co research and development in process for fiscal 2017 was $159.17M.
| Period end | Research and Development in Process 3 month | Research and Development in Process 6 month | Research and Development in Process 9 month | Research and Development in Process 9 month as first filed | Research and Development in Process 12 month | Research and Development in Process 12 month as first filed |
|---|---|---|---|---|---|---|
| 2022-12-31 | $37.25M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $50.25M derived: sum of 2 quarters · filed 2023-03-01 | $50.25M derived: sum of 3 quarters · filed 2023-03-01 | $52.25M 10-K · filed 2023-03-01 | ||
| 2022-09-30 | $13.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $13.00M derived: sum of 2 quarters · filed 2022-11-02 | $15.00M 10-Q · filed 2022-11-02 | $45.07M derived: sum of 4 quarters · filed 2023-03-01 | ||
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $2.00M 10-Q · filed 2022-08-03 | $32.07M derived: sum of 3 quarters · filed 2023-03-01 | $25.57M derived: sum of 4 quarters · filed 2023-03-01 | ||
| 2022-03-31 | $2.00M 10-Q · filed 2022-05-04 | $32.07M derived: sum of 2 quarters · filed 2023-03-01 | $25.57M derived: sum of 3 quarters · filed 2023-03-01 | |||
| 2021-12-31 | $30.07M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $23.57M derived: sum of 2 quarters · filed 2023-03-01 | $70.07M 10-K · filed 2023-03-01 | $76.57M 10-K · filed 2022-03-01 | ||
| 2021-09-30 | -$6.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $40.00M 10-Q · filed 2022-11-02 | $46.50M 10-Q · filed 2021-11-03 | |||
| 2021-06-30 | $46.50M 10-Q · filed 2022-08-03 | |||||
| 2020-12-31 | $30.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $30.00M derived: sum of 2 quarters · filed 2023-03-01 | $77.52M 10-K · filed 2023-03-01 | |||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $47.52M 10-Q · filed 2021-11-03 | ||||
| 2020-06-30 | $47.52M 10-Q · filed 2021-08-04 | |||||
| 2017-12-31 | $10.40M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $10.56M derived: sum of 2 quarters · filed 2020-02-26 | $159.17M 10-K · filed 2020-02-26 | |||
| 2017-09-30 | $160.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $148.77M 10-Q · filed 2018-11-07 | ||||
| 2017-06-30 | $148.61M 10-Q · filed 2018-08-08 |